This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter       

Oncology

18
Amgen receives positive CHMP opinion to extend indication of Kyprolis®
Amgen receives positive CHMP opinion to extend indication of Kyprolis®
Read more
NICE recommends Jevtana® to treat eligible patients with advanced prostate cancer
NICE recommends Jevtana® to treat eligible patients with advanced prostate cancer
Read more
Latest developments in intravascular robotics
Read more
Managing chemotherapy extravasations in practice
Read more
AbbVie announces The Lancet Oncology publication of Phase II data for Venetoclax
AbbVie announces The Lancet Oncology publication of Phase II data for Venetoclax
Read more
A novel therapy for high-grade glioma
Read more
Urine FISH for detection of urothelial cancer
Read more
MALDI-MSI: a powerful tool in cancer research
Read more
Treatment of peritoneal surface malignancies
Read more
ESMO CPGs for primary breast cancer
Read more
The management of cutaneous melanoma
Read more
SMC says ‘yes’ to treatment for advanced cervical cancer
SMC says ‘yes’ to treatment for advanced cervical cancer
Read more
New European policy recommendations on cytotoxic drugs
New European policy recommendations on cytotoxic drugs
Read more
Patients with advanced mCRC have a new treatment option as LONSURF® receives EU approval
Patients with advanced mCRC have a new treatment option as LONSURF® receives EU approval
Read more
EADV launches Global Call to Action to protect outdoor workers from skin cancer caused by the sun
EADV launches Global Call to Action to protect outdoor workers from skin cancer caused by the sun
Read more
Selvita files IND application for its novel, dual PIM/FLT3 inhibitor in AML
Selvita files IND application for its novel, dual PIM/FLT3 inhibitor in AML
Read more
Kymab and Heptares enter strategic collaboration to develop novel antibody therapeutics
Kymab and Heptares enter strategic collaboration to develop novel antibody therapeutics
Read more
Merck and Sysmex Inostics receive CE Mark approval for liquid biopsy test for colorectal cancer
Merck and Sysmex Inostics receive CE Mark approval for liquid biopsy test for colorectal cancer
Read more

Popular articles

What the NHS 10-year plan means for hospitals
Genomic data and technology set to power NHS 10-year plan
New NHS operating model and financial incentives explained
Cardiology, respiratory and dermatology to be prioritised in NHS technology expansion
Personalised care plans for majority of complex patients within two years, says Government



 
FOLLOW US

IMPORTANT LINKS

MORE FROM COGORA

© Cogora 2025
Cogora Limited. 1 Giltspur Street, London EC1A 9DD Registered in the United Kingdom. Reg. No. 2147432

Cogora
x